Earnings call transcript: Kitron posts strong Q2 2026 growth, shares fall 7.8%

Kitron reported Q2 2026 EPS of EUR 0.10, beating the EUR 0.0925 forecast (+8.1%) and revenue up 71.8% YoY to EUR 296m, alongside an EBIT margin rising to 9.6% (+90 bps YoY). However, the stock fell 7.82% pre-market to $94.85 as management kept full-year guidance unchanged, citing continued component/PCB supply constraints and execution/conversion risk in 2H. Outlook remains EUR 900m–1.05bn revenue and EUR 84m–108m EBIT for 2026, with management trending toward the top end but unwilling to raise guidance amid tightening electronics allocations.

Analysis

This reads less like a simple earnings beat and more like a proof point that high-reliability electronics is shifting from lowest-cost sourcing to supply-assured sourcing. The winners are companies with qualified European capacity, customer-funded inventory, and enough balance-sheet room to pre-buy strategic parts; the losers are EMS peers that depend on just-in-time conversion or Asia-centric boards, because the bottleneck is now board and processor allocation, not end-demand. The market is likely misreading delayed revenue as demand weakness when it is really a working-capital and qualification bottleneck.

Near term, the main risk is that backlog converts slower than expected, which can suppress reported revenue and create another quarter of negative sentiment even if demand stays intact. Over 1-3 months, the key monitor is whether organic book-to-bill stays above 1.0 and whether margin holds around the mid-9% area; if either slips, the stock may deserve a lower multiple despite the strong backlog. Over 6-18 months, the structural thesis is stronger: defense rearmament, grid capex, and AI/data-center-linked component scarcity should support pricing power for the few suppliers that can actually deliver.

The contrarian view is that the selloff may be overdone because management’s refusal to raise guidance is a conservatism signal, not a demand signal. If supply normalizes, the deferred orders should roll into subsequent quarters, creating a cleaner earnings upgrade cycle than the current guidance implies. What would falsify that view is persistent PCB scarcity into Q4 without corresponding backlog conversion, or a second consecutive quarter of guide refusal despite clear capacity relief.

Key Decisions for Investors

• Long TTM / short JBL for 1-3 months: express the view that advanced PCB scarcity and defense-linked high-reliability demand will support TTM’s mix and pricing more than a diversified EMS peer. Cover if TTM’s gross margin or order commentary shows no pricing lift, or if PCB lead times materially ease.
• Buy ITA on weakness for a 3-6 month proxy trade: if supply constraints are delaying delivery but not demand, defense primes with program backlogs should monetize the rearmament cycle better than contract manufacturers. Thesis breaks if European defense budget timing slips or if order conversion across the supply chain rolls over.
• Do not add to any European EMS name until Q3 confirms conversion: require either an organic book-to-bill above 1.1 or a guide raise before chasing the move. If neither appears, the safer read is that the current quarter was deferred, not re-rated.